北京森妙生物科技

Senmiao Bio is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies for cancer. The company focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies to treat both hematological malignancies and solid tumors. Its lead programs include dual-targeting CAR-T therapies designed to overcome antigen escape and improve patient outcomes in refractory cases. Senmiao Bio leverages its proprietary cell engineering platforms to advance a diverse pipeline of next-generation immunotherapies. The company operates a state-of-the-art R&D facility and is advancing multiple programs through clinical trials in China.